



CONSOLIDATED STRATEGIC INFORMATION GUIDELINES FOR VIRAL HEPATITIS

PLANNING AND TRACKING PROGRESS TOWARDS ELIMINATION

GUIDELINES



World Health
Organization

CONSOLIDATED STRATEGIC INFORMATION GUIDELINES FOR VIRAL HEPATITIS

PLANNING AND TRACKING PROGRESS TOWARDS ELIMINATION

FEBRUARY 2019

GUIDELINES

Consolidated strategic information guidelines for viral hepatitis: planning and tracking progress towards elimination

ISBN 978-92-4-151519-1

© World Health Organization 2019

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition."

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Consolidated strategic information guidelines for viral hepatitis: planning and tracking progress towards elimination. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

CONTENTS

ACKNOWLEDGEMENTS	iv
FUNDING	v
ABBREVIATIONS AND ACRONYMS	vi
EXECUTIVE SUMMARY	vii
BACKGROUND	1
AIMS OF THIS DOCUMENT	3
SURVEILLANCE	4
MONITORING AND EVALUATION FRAMEWORK	10
STRATEGIC INFORMATION AT THE VARIOUS STAGES OF A PROGRAMME	16
ROLE OF MODELLING	18
CONCLUSIONS	19
REFERENCES	20
APPENDICES	24
WEB ANNEXES	
1. Standard operating procedures for enhanced reporting of cases of acute hepatitis (https://apps.who.int/iris/bitstream/handle/10665/280098/WHO-CDS-HIV-19.2-eng.pdf)	
2. Template protocol for surveys to estimate the prevalence of biomarkers of infection with the hepatitis viruses: tool for adaptation and use at country level (https://apps.who.int/iris/bitstream/handle/10665/280099/WHO-CDS-HIV-19.3-eng.pdf)	
3. Protocol for surveillance of the fraction of cirrhosis and hepatocellular carcinoma attributable to viral hepatitis in clinical centres of excellence (https://apps.who.int/iris/bitstream/handle/10665/280097/WHO-CDS-HIV-19.4-eng.pdf)	

ACKNOWLEDGEMENTS

This document was developed by Yvan Hutin, Technical Officer, Strategic Information at the Department of HIV and Global Hepatitis Programme. The following staff members of the Department also contributed to the development of the document: Andrew Ball, Marc Bulterys, Philippa Easterbrook, Hande Harmanci, Tomoyuki Hayashi, Sarah Hess, David Lowrance, Daniel Low-Beer, Jesus Maria Garcia-Calleja, Fabio Mesquita and Judith Van Holten.

This document benefited from the work of colleagues at the WHO regional offices, including comments and suggestions on the draft document and pilot-testing during country missions. Contributors included Olufunmilayo Lesi (Regional Office for Africa); Nicholas Walsh and Monica Alonso (Regional Office for the Americas); Joumana Hermez and Ahmed Sabry (Regional Office for the Eastern Mediterranean); Antons Mozalevskis (Regional Office for Europe), Mukta Sharma and Bharat Rewari (Regional Office for South-East Asia), Linh-Vi Le and Po-Lin Chan (Regional Office for the Western Pacific).

The members of the Viral Hepatitis Strategic Information and Modelling Reference Group of WHO framed the need for this document and provided input on the draft. These include Laith Abu-Raddad, Weill Cornell Medical College Qatar, Doha, Qatar; Rakesh Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India; Benjamin Cowie, WHO Collaborating Centre for Viral Hepatitis, Doherty Institute, Melbourne, Australia; John Edmunds, London School of Hygiene and Tropical Medicine, London, United Kingdom (UK); Timothy Hallet, Imperial College London, London, UK; Sharon Hutchinson, Health Protection Scotland, Glasgow, UK; Wilford Kirungi, Ministry of Health, Kampala, Uganda; Homie Razavi, Center for Disease Analysis, Lafayette, Colorado, United States of America (USA); David B. Rein, University of Chicago, Atlanta, USA; Mehlika Toy, Stanford University School of Medicine, Palo Alto, CA, USA.

Dr Hassaan Zahid (Médecins Sans Frontières, Pakistan) and John Ward (Director, Program for Viral Hepatitis Elimination Task Force for Global Health) provided useful comments on the draft.

FUNDING

These guidelines were developed with funding support from UNITAID, and the US Centers for Disease Control and Prevention, Division of Viral Hepatitis.

ABBREVIATIONS AND ACRONYMS

DHIS2	District Health Information System 2 (software)
EPI	Expanded Programme on Immunization
ERC	WHO research Ethics Review Committee
GHSS	Global Health Sector Strategy
HBsAg	hepatitis B surface antigen
HBV	hepatitis B virus
HCC	hepatocellular carcinoma
HCV	hepatitis C virus
ICER	incremental cost–effectiveness ratio
Ig	immunoglobulin
SARA	Service Availability and Readiness Assessment
SDG	Sustainable Development Goal

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_25355

